Rhenman & Partners Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.3M	Sell	100,841 -24,650	-20%	-$3.27M	1.64%	19
2025 Q4	$17.8M	Buy	125,491 +10,774	+9%	+$1.56M	1.66%	21
2025 Q3	$16.1M	Sell	114,717 -34,500	-23%	-$4.67M	1.78%	21
2025 Q2	$18.8M	Buy	149,217 +59,400	+66%	+$6.81M	2.37%	10
2025 Q1	$9.93M	Sell	89,817 -10,500	-10%	-$1.33M	1.14%	32
2024 Q4	$13.7M	Buy	100,317 +28,567	+40%	+$3.53M	1.41%	29
2024 Q3	$8.27M	Sell	71,750 -3,805	-5%	-$522K	0.67%	51
2024 Q2	$10.4M	Buy	75,555 +16,555	+28%	+$2.27M	1%	36
2024 Q1	$8.14M	Sell	59,000 -3,000	-5%	-$410K	0.77%	44
2023 Q4	$8.17M	Buy	62,000 +7,434	+14%	+$856K	0.82%	45
2023 Q3	$6.14M	Buy	54,566 +14,566	+36%	+$1.53M	0.66%	44
2023 Q2	$3.77M	Sell	40,000 -30,000	-43%	-$2.93M	0.4%	62
2023 Q1	$6.94M	Sell	70,000 -15,000	-18%	-$1.56M	0.76%	44
2022 Q4	$10.2M	Buy	85,000 +2,000	+2%	+$234K	1.06%	36
2022 Q3	$9.55M	Sell	83,000 -12,000	-13%	-$1.22M	1%	35
2022 Q2	$9.26M	Sell	95,000 -10,000	-10%	-$923K	1.05%	36
2022 Q1	$9.84M	Sell	105,000 -46,100	-31%	-$3.91M	0.97%	43
2021 Q4	$12.8M	Buy	151,100 +56,100	+59%	+$5.16M	0.85%	44
2021 Q3	$9.11M	Sell	95,000 -10,000	-10%	-$945K	0.64%	50
2021 Q2	$10.2M	Sell	105,000 -50,000	-32%	-$4.79M	0.69%	56
2021 Q1	$15.1M	Buy	155,000 +5,000	+3%	+$524K	1.05%	40
2020 Q4	$14.4M	Buy	150,000 +75,000	+100%	+$7.24M	1.17%	38
2020 Q3	$7.21M	Hold	75,000	–	–	0.64%	53
2020 Q2	$9.15M	Sell	75,000 -55,000	-42%	-$6.08M	0.99%	42
2020 Q1	$11.3M	Buy	130,000 +10,000	+8%	+$979K	1.58%	25
2019 Q4	$12.9M	Sell	120,000 -29,600	-20%	-$3.1M	1.41%	29
2019 Q3	$13.5M	Sell	149,600 -30,400	-17%	-$2.84M	1.69%	22
2019 Q2	$15.2M	Buy	180,000 +2,909	+2%	+$239K	1.67%	26
2019 Q1	$15.6M	Sell	177,091 -24,000	-12%	-$2.01M	1.82%	20
2018 Q4	$14.4M	Buy	201,091 +119,414	+146%	+$11.4M	1.64%	25
2018 Q3	$10M	Sell	81,677 -28,700	-26%	-$3.26M	1.01%	47
2018 Q2	$10.8M	Buy	110,377 +377	+0.3%	+$33.7K	1.11%	44
2018 Q1	$9.12M	Sell	110,000 -7,969	-7%	-$673K	1.12%	38
2017 Q4	$9.15M	Buy	117,969 +2,969	+3%	+$203K	1.24%	31
2017 Q3	$7.05M	Sell	115,000 -5,000	-4%	-$264K	0.9%	41
2017 Q2	$5.52M	Buy	120,000 +35,000	+41%	+$1.7M	0.79%	50
2017 Q1	$3.68M	Buy	85,000 +45,000	+113%	+$1.93M	0.58%	63
2016 Q4	$1.55M	Hold	40,000	–	–	0.3%	79
2016 Q3	$2.03M	Hold	40,000	–	–	0.32%	80
2016 Q2	$1.82M	Sell	40,000 -20,000	-33%	-$921K	0.32%	79
2016 Q1	$2.37M	Buy	+60,000	New	+$2.38M	0.47%	71

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rhenman & Partners Asset Management's NBIX Position: Q1 2026 in Review

Rhenman & Partners Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 20% in Q1 2026, selling an estimated $3.27M and leaving 100,841 shares worth $13.3M. The position accounts for 1.64% of the portfolio, ranked #19.

Rhenman & Partners Asset Management first reported a position in NBIX in Q1 2016 and has held it in 41 quarters since. The position peaked at $18.8M in Q2 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Rhenman & Partners Asset Management held 100,841 shares of Neurocrine Biosciences worth $13.3M as of Q1 2026.
Rhenman & Partners Asset Management sold 24,650 Neurocrine Biosciences shares in Q1 2026, an estimated $3.27M.
Neurocrine Biosciences made up 1.64% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #19 holding.
Rhenman & Partners Asset Management first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 41 quarters since.
Rhenman & Partners Asset Management's Neurocrine Biosciences position peaked at $18.8M in Q2 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.